April 18th 2024
Meta-analysis of 11 phase 3 trials shows SGLT2 inhibitors reduce cardiovascular event risk by 9% across diverse patient populations.
Healthy Beverage Choices May Lower Mortality Risk in Adults with Diabetes
April 20th 2023An analysis of adults with T2D found a higher intake of sugar-sweetened beverages was associated with higher all-cause mortality and CVD incidence, whereas healthier beverage options were inversely associated with all-cause mortality.
Diabetes Dialogue: News on Abbott Readers & CMS Expansion of CGM Availability
April 19th 2023Diana Isaacs, PharmD, and Natalie Bellini, DNP, sit down to discuss the implications of increased CGM access through a recent CMS expansion and take a deep dive into the latest Abbott news, including dispelling misconceptions surrounding the recall announcement.
Study: Insulin Shelf Life Could Be 4 Times Longer than Previously Reported
April 12th 2023A new pilot study assessing the shelf life of insulin when stored at room temperature during the summer in India suggests most insulins maintained 95% potency or greater at 4 months relative to refrigerated insulin.
FDA Issues Class I Recall of Abbott FreeStyle Readers for Risk of Overheating, Fire
April 6th 2023Announced on April 6, the recall, which is the most serious of its kind, includes all Readers used with the FreeStyle Libre, FreeStyle Libre 14 day, and FreeStyle Libre 2 Flash Glucose Monitoring Systems distributed from November 2017-February 2023, which totals more than 4 million devices in the US.
Transcatheter Arterialization Could Revolutionize Treatment of Limb-Threatening Ischemia
March 31st 2023Data from the PROMISE II study detail the effects of transcatheter arterialization procedures with the LimFlow System for reducing the rate of amputation in people with chronic limb-threatening ischemia.
10 Years of SGLT2 Inhibitors: A Decade of Redefining Cardiometabolic Care
March 29th 2023This feature articles commemorates the 10-year anniversary of the FDA's first approval of an SGLT2 inhibitor on March 29, 2013 and provides a snapshot at the class's ascent into the treatment algorithms and guidelines for type 2 diabetes, heart failure, and chronic kidney disease.
Diabetes Dialogue: 10 Years of SGLT2s, Insulin for All, and Pemvidutide
March 29th 2023In this episode, hosts celebrate the 10-year anniversary of the approval of the first SGLT2 inhibitor, discuss announcements related to insulin pricing, and take a deep dive into 24-week data from the MOMENTUM trial.
Endocrine Case Report: Ear Pain in Diabetes
March 27th 2023Our latest endocrine case report from Brady Pregerson, MD, features a patient in their mid-70s with a history of diabetes mellitus and end-stage kidney disease presenting with 6 days of gradually worsening right ear pain. Can you determine the correct diagnosis?
Metformin Could Lower Osteoarthritis Risk in Type 2 Diabetes
March 26th 2023A retrospective analysis comparing propensity score matched metformin users against sulfonylurea users, results of the study indicate metformin use was associated with a 24% reduction in relative risk of developing osteoarthritis.
Once-Weekly Basal Insulin Proves Noninferiority to Daily Degludec in Insulin-Naive Patients
March 24th 2023A phase 2 trial comparing once weekly basal insulin Fc against once daily insulin degludec, results of the study will help provide the basis for forthcoming phase 3 research examining the agent.
Diabetes Dialogue: CMS Expansion Ushers in New Age of CGM Access
March 17th 2023In this in-studio episode, hosts offer insight and perspective into what the news regarding the CMS expansion of CGM coverage means for people with diabetes and take a deep dive into a recent announcement of an FDA clearance for Abbott's FreeStyle Libre sensors.
FDA Accepts sNDA for Empagliflozin in Children with Type 2 Diabetes Aged 10 & Older
March 8th 2023If approved, Boehringer Ingelheim and Eli Lilly and Company's SGLT2 inhibitor would be the first agent in the class with an indication as an adjunct to diet and exercise for improving glycemic control in children with type 2 diabetes aged 10 years and older.
FreeStyle Libre Sensors Cleared for Integration with Automated Insulin Delivery Systems
March 6th 2023The US FDA has granted clearance to the FreeStyle Libre 2 and FreeStyle Libre 3 sensors for integration with automated insulin delivery systems. Abbott, which noted ongoing collaborations with Insulet and Tandem, expects the modified sensors to be available in the US later this year.
Diabetes Community Reacts to Insulin Price Reduction by Eli Lilly and Company
March 2nd 2023After Eli Lilly and Company announced major reductions in list prices for multiple insulin products, the community rejoiced at the though of taking a major step forward toward equitable access to insulin. Learn more about the reaction from major organizations and those within the field.
Diabetes Dialogue: Practical Updates in Pediatric Diabetes, with Stuart Weinzimer, MD
March 2nd 2023In this episode, Stuart Weinzimer, MD sits down with hosts for a discussion on his research and experience with diabetes technology, the need to focus on patient-reported outcomes in pediatric diabetes, and strategies for meeting the practical needs of individuals with diabetes.